# A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

> **NCT05636215** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 368 (estimated)

## Conditions studied

- Locally Advanced Unresectable or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** IBI354

## Key facts

- **NCT ID:** NCT05636215
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-10-31
- **Target enrollment:** 368 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636215, "A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05636215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*